Literature DB >> 33440868

Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas.

Jungho Kim1.   

Abstract

Breast cancer is the most common cancer among women worldwide. MicroRNAs (miRNAs or miRs) play an important role in tumorigenesis, and thus, they have been identified as potential targets for translational research with diagnostic, prognostic, and therapeutic markers. This study aimed to identify differentially expressed (DE) miRNAs in breast cancer using the Cancer Genome Atlas. The miRNA profiles of 755 breast cancer tissues and 86 adjacent non-cancerous breast tissues were analyzed using Multi Experiment Viewer; miRNA-mRNA network analyses and constructed KEGG pathways with the predicted target genes were performed. The clinical relevance of miRNAs was investigated using area under the receiver operating characteristic curve (AUC) analysis, sensitivity, and specificity. The analysis identified 28 DE miRNAs in breast cancer tissues, including nine upregulated and 19 downregulated miRNAs, compared to non-cancerous breast tissues (p < 0.001). The AUC for each DE miRNA, miR-10b, miR-21, miR-96, miR-99a, miR-100, miR-125b-1, miR-125b-2, miR-139, miR-141, miR-145, miR-182, miR-183, miR-195, miR-200a, miR-337, miR-429, and let-7c, exceeded 0.9, indicating excellent diagnostic performance in breast cancer. Moreover, 1381 potential target genes were predicted using the prediction database tool, miRNet. These genes are related to PD-L1 expression and PD-1 checkpoint in cancer, MAPK signaling, apoptosis, and TNF pathways; hence, they regulate the development, progression, and immune escape of cancer. Thus, these 28 miRNAs can serve as prospective biomarkers for the diagnosis of breast cancer. Taken together, these results provide insight into the pathogenic mechanisms and potential therapies for breast cancer.

Entities:  

Keywords:  TCGA; breast cancer; diagnosis; microRNAs; translational research

Year:  2021        PMID: 33440868      PMCID: PMC7827427          DOI: 10.3390/diagnostics11010107

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  66 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

3.  A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells.

Authors:  Maxine Umeh-Garcia; Catalina Simion; Pui-Yan Ho; Neelu Batra; Anastasia L Berg; Kermit L Carraway; Aiming Yu; Colleen Sweeney
Journal:  Cancer Res       Date:  2019-11-06       Impact factor: 12.701

4.  Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.

Authors:  Penn Muluhngwi; Abirami Krishna; Stephany L Vittitow; Joshua T Napier; Kirsten M Richardson; Mackenzie Ellis; Justin L Mott; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2016-12-13       Impact factor: 8.679

Review 5.  Use of cell free DNA in breast oncology.

Authors:  Jenna VanLiere Canzoniero; Ben Ho Park
Journal:  Biochim Biophys Acta       Date:  2016-03-22

6.  Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.

Authors:  Corinna Eichelser; Dieter Flesch-Janys; Jenny Chang-Claude; Klaus Pantel; Heidi Schwarzenbach
Journal:  Clin Chem       Date:  2013-06-07       Impact factor: 8.327

Review 7.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Authors:  Rajesha Rupaimoole; Frank J Slack
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

8.  Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis.

Authors:  Nancy Rodig; Timothy Ryan; Jessica A Allen; Hong Pang; Nir Grabie; Tatyana Chernova; Edward A Greenfield; Spencer C Liang; Arlene H Sharpe; Andrew H Lichtman; Gordon J Freeman
Journal:  Eur J Immunol       Date:  2003-11       Impact factor: 5.532

9.  Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.

Authors:  Krithika N Kodumudi; Jessica Siegel; Amy M Weber; Ellen Scott; Amod A Sarnaik; Shari Pilon-Thomas
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

10.  Tumor-suppressor role of miR-139-5p in endometrial cancer.

Authors:  JinHui Liu; ChunYu Li; Yi Jiang; YiCong Wan; ShuLin Zhou; WenJun Cheng
Journal:  Cancer Cell Int       Date:  2018-04-02       Impact factor: 5.722

View more
  6 in total

1.  Aminoflavone upregulates putative tumor suppressor miR-125b-2-3p to inhibit luminal A breast cancer stem cell-like properties.

Authors:  Nicole Mavingire; Petreena Campbell; Tiantian Liu; Jonathan Wooten; Salma Khan; Xin Chen; Jason Matthews; Charles Wang; Eileen Brantley
Journal:  Precis Clin Med       Date:  2022-03-28

2.  Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women.

Authors:  Thangarajan Rajkumar; Sathyanarayanan Amritha; Veluswami Sridevi; Gopisetty Gopal; Kesavan Sabitha; Sundersingh Shirley; Rajaraman Swaminathan
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

3.  Immune Checkpoint and Telomerase Crosstalk Is Mediated by miRNA-138 in Bladder Cancer.

Authors:  Hajar El Ahanidi; Meryem El Azzouzi; Chaimae Hafidi Alaoui; Mohammed Tetou; Mounia Bensaid; Imane Chaoui; Laila Benbacer; Ilias Hassan; Mohamed Oukabli; Katarzyna Michaud; Ahmed Ameur; Abderrahmane Al Bouzidi; Mohammed El Mzibri; Camilla Jandus; Mohammed Attaleb
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

4.  Identification of MicroRNAs as Potential Blood-Based Biomarkers for Diagnosis and Therapeutic Monitoring of Active Tuberculosis.

Authors:  Junseong Kim; Heechul Park; Sung-Bae Park; Eun Ju Lee; Min-A Je; Eunsol Ahn; Bora Sim; Jiyoung Lee; Hyunwoo Jin; Kyung Eun Lee; Sang-Nae Cho; Young Ae Kang; Hyejon Lee; Sunghyun Kim; Jungho Kim
Journal:  Diagnostics (Basel)       Date:  2022-02-01

5.  Effect of microrna-138 on epithelial-Mesenchymal transition and invasion of breast cancer cells by targeting semaphorin 4C.

Authors:  HuiJuan Liu; Hui Ye; Xinzheng Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 6.  miRNAs in Cancer (Review of Literature).

Authors:  Beata Smolarz; Adam Durczyński; Hanna Romanowicz; Krzysztof Szyłło; Piotr Hogendorf
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.